Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.

Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Moseley, R. P., Davies, A. G., Richardson, R. B., Zalutsky, M., Carrell, S., Fabre, J., Slack, N., Bullimore, J., Pizer, B., Papanastassiou, V.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971477/
https://www.ncbi.nlm.nih.gov/pubmed/2223581
_version_ 1782134918920273920
author Moseley, R. P.
Davies, A. G.
Richardson, R. B.
Zalutsky, M.
Carrell, S.
Fabre, J.
Slack, N.
Bullimore, J.
Pizer, B.
Papanastassiou, V.
author_facet Moseley, R. P.
Davies, A. G.
Richardson, R. B.
Zalutsky, M.
Carrell, S.
Fabre, J.
Slack, N.
Bullimore, J.
Pizer, B.
Papanastassiou, V.
author_sort Moseley, R. P.
collection PubMed
description Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months.
format Text
id pubmed-1971477
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19714772009-09-10 Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Moseley, R. P. Davies, A. G. Richardson, R. B. Zalutsky, M. Carrell, S. Fabre, J. Slack, N. Bullimore, J. Pizer, B. Papanastassiou, V. Br J Cancer Research Article Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months. Nature Publishing Group 1990-10 /pmc/articles/PMC1971477/ /pubmed/2223581 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Moseley, R. P.
Davies, A. G.
Richardson, R. B.
Zalutsky, M.
Carrell, S.
Fabre, J.
Slack, N.
Bullimore, J.
Pizer, B.
Papanastassiou, V.
Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
title Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
title_full Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
title_fullStr Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
title_full_unstemmed Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
title_short Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
title_sort intrathecal administration of 131i radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971477/
https://www.ncbi.nlm.nih.gov/pubmed/2223581
work_keys_str_mv AT moseleyrp intrathecaladministrationof131iradiolabelledmonoclonalantibodyasatreatmentforneoplasticmeningitis
AT daviesag intrathecaladministrationof131iradiolabelledmonoclonalantibodyasatreatmentforneoplasticmeningitis
AT richardsonrb intrathecaladministrationof131iradiolabelledmonoclonalantibodyasatreatmentforneoplasticmeningitis
AT zalutskym intrathecaladministrationof131iradiolabelledmonoclonalantibodyasatreatmentforneoplasticmeningitis
AT carrells intrathecaladministrationof131iradiolabelledmonoclonalantibodyasatreatmentforneoplasticmeningitis
AT fabrej intrathecaladministrationof131iradiolabelledmonoclonalantibodyasatreatmentforneoplasticmeningitis
AT slackn intrathecaladministrationof131iradiolabelledmonoclonalantibodyasatreatmentforneoplasticmeningitis
AT bullimorej intrathecaladministrationof131iradiolabelledmonoclonalantibodyasatreatmentforneoplasticmeningitis
AT pizerb intrathecaladministrationof131iradiolabelledmonoclonalantibodyasatreatmentforneoplasticmeningitis
AT papanastassiouv intrathecaladministrationof131iradiolabelledmonoclonalantibodyasatreatmentforneoplasticmeningitis

Ejemplares similares